Gilead Sciences, through its Kite Pharma subsidiary, acquired Interius BioTherapeutics for $350 million to expand its capabilities in in vivo CAR-T cell therapies. This approach genetically modifies immune cells within the patient’s body, offering a potentially simpler and more scalable alternative to traditional ex vivo CAR-T therapies. The acquisition aligns with broader industry trends emphasizing safer, scalable cell therapy modalities.